I generally try to consider both the positives and negatives of every stock I analyze, but that has gotten increasingly difficult with Weight Watchers (NYSE:WTW). I have long had my issues with this management team, and I believe management errors have finally started to take their toll on the valuation. While I do believe the brand carries considerable value and that this could be a highly attractive business if run properly, I have little confidence that this team can do it.

Fourth Quarter Results Pretty Mediocre
Although Weight Watchers' fourth quarter performance was better than expected, the absolute numbers weren't all that impressive.

Revenue rose about 2% as reported, better than the more or less flat performance expected by sell-side analysts. Meeting revenue fell more than 3% on weaker attendance across the board, but higher revenue-per-attendee appeared to drive better than expected results. Online was also pretty solid, with revenue growth of a little less than 18%. Product revenue was flat for the quarter.

Margins were mixed. While the strength in the online business helped, gross margin improved about 30 basis points and missed sell-side targets. Although the company increased marketing spend less than expected, SG&A expenses were up more than 20% and operating income fell more than 7%. So although Weight Watchers did beat EPS expectations by 9 cents, about three of that came from lower taxes, and the rest came from revenue.

SEE: Understanding The Income Statement

Guidance and Attendance Numbers Suggest Trouble
Although it's important to note that meeting revenue was better than most analysts expected, I think the attendance numbers should give investors pause. North American attendance dropped more than 14% after a 9% drop in the third quarter, while paid weeks declined by more than 7%. Attendance in the United Kingdom was down nearly 22%, and attendance in continental Europe was up just 1% (after climbing 5% in the third quarter).

Management had plenty of things to blame for these trends, as well as the poor guidance. Apparently meeting recruitment came in well below plan and the company's marketing plans were knocked off track by Jessica Simpson's pregnancy.

I think this is only part of the problem, though. I think Weight Watchers has failed to develop compelling new products that add value to the user/client experience. I think that could be particularly dangerous in the online business, where dieters can increasingly choose free apps or ad-supported website in lieu of paying $19 a month for a subscription.

Whatever the causes, the outlook for 2013 is pretty grim. Against a prior sell-side average estimate of $4.75 per share in earnings for Weight Watchers, management guidance gave a midpoint of $3.75.

This Is a Hard Business for Everybody
While I clearly don't think much of Weight Watchers management, I will acknowledge that weight management/weight loss has proved to be a very difficult business for almost everybody who has tried. Nutrisystem (Nasdaq:NTRI), for instance, has done even worse in terms of both operating and stock market performance. Arguably the only strong name in the space is Nestle (OTC:NSRGY) and its Jenny Craig business, but Nestle doesn't provide much detail and Nestle's nutrition business is exceptionally well-run by most standards.

I'll be curious to see whether recently approved weight loss drugs have any meaningful impact on Weight Watchers. Both of the drugs developed by Arena Pharmaceuticals (Nasdaq:ARNA) and Vivus (Nasdaq:VVUS) have serious drawbacks (Arena's with efficacy and Vivus with safety), but I don't doubt that potential Weight Watchers customers will be tempted to try these drugs. While I don't expect either to be a blockbuster, both could make 2013 a little more challenging for Weight Watchers.

SEE: 5 Must-Have Metrics For Value Investors

The Bottom Line
As I said in the beginning, I believe that the basic Weight Watchers model can work - particularly if the company can do more to forge ties with health insurance companies and large enterprises looking to improve employee health and overall healthcare costs. Barring something major (like a change in the CEO), though, I don't have that much confidence that the company will do better.

With a debt-laden balance sheet and perhaps only mid-single digit free cash flow growth over the long term, I'd give these shares a pass.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  7. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  8. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  9. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  10. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center